About
The receipt of a total knee (TKR) or hip replacement (THR) has commonly been used in clinical trials as an outcome measure of “late-stage” osteoarthritis (OA). However, total joint replacement outcomes are highly variable, dependent on a patient’s access and preference for surgery, the surgeon’s preference, socio-economic and geographical factors.
There have been calls by the clinical trial community and clinical regulators to define a clinical endpoint for “late stage OA”, leading to the development of a new composite measure that can be used as both an outcome measure or inclusion/exclusion criteria in clinical trials. The aims of this working group are to generate and define a set of candidate target domains to be included in all studies that aim to prevent or reduce TKR or THR, with a view to future developing a composite measure of the late-stage OA.
Current Stage in the OMERACT Process
The group is identifying which outcomes best capture progression in late-stage osteoarthritis. Findings from ongoing reviews will inform development of a new composite measure.
Latest Update
Undertaking a two-stage mixed methods study to identify, describe and agree on a core domain set for people with symptomatic late-stage osteoarthritis. We are currently undertaking two reviews to inform this work. A scoping review of quantitative studies to identify which outcome measures have previously been used for this population and a systematic review of qualitative studies to identify and understand what domains are important to people with/who have had symptomatic late-stage OA.
Recent Milestones Achieved
-
Completed data extraction for qualitative systematic review
-
Completed full-text screening for the scoping review
-
Upcoming Activities and Deliverables
-
Steering Committee meeting in March to discuss the next steps
-
Begin data extraction for a scoping review
